Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Kohrt, R. Houot, A. Marabelle, H. Cho, Keren Osman, M. Goldstein, R. Levy, J. Brody (2012)
Combination strategies to enhance antitumor ADCC.Immunotherapy, 4 5
J. Elliott, J. McMahon, Christina Chang, Sulggi Lee, W. Hartogensis, Namandjé Bumpus, R. Savic, J. Roney, R. Hoh, A. Solomon, M. Piatak, R. Gorelick, J. Lifson, P. Bacchetti, S. Deeks, S. Lewin (2015)
Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study.The lancet. HIV, 2 12
A. Tsai, A. Irrinki, J. Kaur, T. Cihlar, G. Kukolj, D. Sloan, J. Murry (2017)
Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral TherapyJournal of Virology, 91
J. Horwitz, Y. Bar-On, Ching-Lan Lu, D. Fera, Ainsley Lockhart, J. Lorenzi, Lilian Nogueira, Jovana Golijanin, J. Scheid, M. Seaman, A. Gazumyan, S. Zolla-Pazner, M. Nussenzweig (2017)
Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In VivoCell, 170
B. Julg, L. Dee, J. Ananworanich, D. Barouch, K. Bar, M. Caskey, D. Colby, Liza Dawson, K. Dong, K. Dubé, J. Eron, J. Frater, R. Gandhi, R. Geleziunas, P. Goulder, G. Hanna, R. Jefferys, Rowena Johnston, D. Kuritzkes, Jonathan Li, Udom Likhitwonnawut, J. Lunzen, J. Martinez-Picado, V. Miller, L. Montaner, D. Nixon, D. Palm, G. Pantaleo, H. Peay, D. Persaud, J. Salzwedel, K. Salzwedel, T. Schacker, Virginia Sheikh, O. Søgaard, S Spudich, K. Stephenson, J. Sugarman, Jeff Taylor, P. Tebas, C. Tiemessen, R. Tressler, C. Weiss, Lu Zheng, M. Robb, N. Michael, J. Mellors, S. Deeks, B. Walker (2019)
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.The lancet. HIV, 6 4
This study demonstrated the systemic effects of TLR9 agonist treatment in HIVinfected individuals including pronounced upregulation of antiviral proteins in the GALT
T. Schoofs, Florian Klein, Florian Klein, Florian Klein, Malte Braunschweig, Malte Braunschweig, Edward Kreider, Anna Feldmann, Lilian Nogueira, Thiago Oliveira, J. Lorenzi, E. Parrish, G. Learn, A. West, P. Bjorkman, S. Schlesinger, M. Seaman, Julie Czartoski, M. McElrath, N. Pfeifer, B. Hahn, M. Caskey, M. Nussenzweig, M. Nussenzweig (2016)
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1Science, 352
J. Scheid, J. Horwitz, Y. Bar-On, Edward Kreider, Ching-Lan Lu, J. Lorenzi, Anna Feldmann, Malte Braunschweig, Lilian Nogueira, Thiago Oliveira, I. Shimeliovich, R. Patel, L. Burke, Yehuda Cohen, S. Hadrigan, A. Settler, M. Witmer-Pack, Jr. West, B. Juelg, T. Keler, T. Hawthorne, B. Zingman, R. Gulick, N. Pfeifer, G. Learn, M. Seaman, P. Bjorkman, F. Klein, S. Schlesinger, B. Walker, B. Hahn, M. Nussenzweig, M. Caskey (2016)
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruptionNature, 535
G. Khoury, G. Darcis, M. Lee, S. Bouchat, Benoit Driessche, D. Purcell, C. Lint (2018)
The Molecular Biology of HIV Latency.Advances in experimental medicine and biology, 1075
Wenxin Xu, Monica Jones, Bai Liu, Xiao-yun Zhu, C. Johnson, A. Edwards, Lin Kong, Emily Jeng, Kai-ping Han, W. Marcus, M. Rubinstein, P. Rhode, H. Wong (2013)
Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma.Cancer research, 73 10
D. Wei, Vicki Chiang, Elizabeth Fyne, M. Balakrishnan, Tiffany Barnes, M. Graupe, J. Hesselgesser, A. Irrinki, J. Murry, G. Stepan, Kirsten Stray, A. Tsai, Helen Yu, J. Spindler, Mary Kearney, C. Spina, D. McMahon, J. Lalezari, D. Sloan, J. Mellors, R. Geleziunas, T. Cihlar (2014)
Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical DosingPLoS Pathogens, 10
S. Deeks, S. Lewin, A. Ross, J. Ananworanich, M. Benkirane, P. Cannon, N. Chomont, D. Douek, J. Lifson, Y. Lo, D. Kuritzkes, D. Margolis, J. Mellors, D. Persaud, J. Tucker, F. Barré-Sinoussi, G. Alter, J. Auerbach, B. Autran, D. Barouch, G. Behrens, M. Cavazzana, Zhiwei Chen, É. Cohen, G. Corbelli, S. Eholie, N. Eyal, S. Fidler, L. Garcia, Cynthia Grossman, G. Henderson, T. Henrich, R. Jefferys, H. Kiem, J. McCune, K. Moodley, P. Newman, M. Nijhuis, M. Nsubuga, M. Ott, S. Palmer, D. Richman, A. Sáez-Cirión, M. Sharp, J. Siliciano, G. Silvestri, J. Singh, B. Spire, Jeffrey Taylor, M. Tolstrup, S. Valente, J. Lunzen, R. Walensky, I. Wilson, J. Zack (2016)
International AIDS Society global scientific strategy: towards an HIV cure 2016Nature Medicine, 22
Rasmus Offersen, S. Nissen, T. Rasmussen, L. Østergaard, P. Denton, O. Søgaard, M. Tolstrup (2016)
A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T CellsJournal of Virology, 90
S. Leth, M. Schleimann, S. Nissen, J. Højen, R. Olesen, Mette Graversen, S. Jørgensen, A. Sofi, P. Denton, A. Mørk, K. Krogsgaard, L. Østergaard, T. Rasmussen (2016)
Combined eff ect of Vacc-4 x , recombinant human granulocyte macrophage colony-stimulating factor vaccination , and romidepsin on the HIV-1 reservoir ( REDUC ) : a single-arm , phase 1 B / 2 A trial
K. Agarwal, S. Ahn, M. Elkhashab, A. Lau, A. Gaggar, A. Bulusu, X. Tian, A. Cathcart, J. Woo, G. Subramanian, P. Andreone, H. Kim, W. Chuang, M. Nguyen (2018)
Safety and efficacy of vesatolimod (GS‐9620) in patients with chronic hepatitis B who are not currently on antiviral treatmentJournal of Viral Hepatitis, 25
J. Gunst, M. Tolstrup, O. Søgaard (2017)
Beyond antiretroviral therapy: early interventions to control HIV-1 infection.AIDS, 31 12
T. Henrich, Emily Hanhauser, F. Marty, M. Sirignano, S. Keating, Tzong-Hae Lee, Yvonne Robles, B. Davis, Jonathan Li, Andrea Heisey, A. Hill, M. Busch, P. Armand, R. Soiffer, M. Altfeld, D. Kuritzkes (2014)
Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell TransplantationAnnals of Internal Medicine, 161
L. Azzoni, A. Foulkes, E. Papasavvas, A. Mexas, K. Lynn, K. Mounzer, P. Tebas, J. Jacobson, I. Frank, M. Busch, S. Deeks, M. Carrington, U. O’Doherty, J. Kostman, L. Montaner (2013)
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration.The Journal of infectious diseases, 207 2
S. Riddler, M. Para, C. Benson, A. Mills, M. Ramgopal, E. Dejesus, C. Brinson, J. Cyktor, J. Mellors, Shuang Guo, B. Doehle, S. Markova, H. Patel, H. Graham, J. Hesselgesser, R. Geleziunas, D. Brainard, S. McCallister, Devi SenGupta (2019)
Vesatolimod (GS-9620) is safe and pharmacodynamically active in HIV-infected individualsJournal of Virus Eradication
S. Morón-López, P. Kim, O. Søgaard, M. Tolstrup, J. Wong, S. Yukl (2019)
Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individualsAIDS, 33
C. Garrido, M. Abad-Fernández, M. Tuyishime, J. Pollara, G. Ferrari, N. Soriano-Sarabia, D. Margolis (2018)
Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex VivoJournal of Virology, 92
J. Niessl, A. Baxter, Pilar Mendoza, M. Jankovic, Yehuda Cohen, Allison Butler, Ching-Lan Lu, M. Dubé, I. Shimeliovich, H. Gruell, F. Klein, M. Caskey, M. Nussenzweig, D. Kaufmann (2020)
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunityNature Medicine, 26
Elena Bekerman, J. Hesselgesser, B. Carr, M. Nagel, Magdeleine Hung, Adele Wang, Lance Stapleton, A. Gegerfelt, Hanne Elyard, J. Lifson, R. Geleziunas (2019)
PD-1 Blockade and TLR7 Activation Lack Therapeutic Benefit in Chronic Simian Immunodeficiency Virus-Infected Macaques on Antiretroviral TherapyAntimicrobial Agents and Chemotherapy, 63
A. Krarup, M. Abdel-Mohsen, M. Schleimann, Line Vibholm, P. Engen, A. Dige, B. Wittig, M. Schmidt, S. Green, A. Naqib, A. Keshavarzian, Xutao Deng, R. Olesen, A. Petersen, T. Benfield, L. Østergaard, T. Rasmussen, J. Agnholt, J. Nyengaard, A. Landay, O. Søgaard, S. Pillai, M. Tolstrup, P. Denton (2017)
The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colonMucosal immunology, 11
A. Krieg (2006)
Therapeutic potential of Toll-like receptor 9 activationNature Reviews Drug Discovery, 5
T. Rasmussen, M. Tolstrup, O. Søgaard (2016)
Reversal of Latency as Part of a Cure for HIV-1.Trends in microbiology, 24 2
T. Rasmussen, M. Tolstrup, C. Brinkmann, R. Olesen, C. Erikstrup, A. Solomon, A. Winckelmann, S. Palmer, C. Dinarello, M. Buzón, M. Lichterfeld, S. Lewin, L. Østergaard, O. Søgaard (2014)
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.The lancet. HIV, 1 1
A. Winckelmann, K. Barton, B. Hiener, T. Schlub, W. Shao, T. Rasmussen, L. Østergaard, O. Søgaard, M. Tolstrup, S. Palmer (2017)
Romidepsin-induced HIV-1 viremia during effective ART contains identical viral sequences with few deleterious mutations.AIDS
Ariel Halper-Stromberg, Ching-Lan Lu, F. Klein, J. Horwitz, S. Bournazos, Lilian Nogueira, Thomas Eisenreich, Cassie Liu, A. Gazumyan, Uwe Schaefer, Rebecca Furze, M. Seaman, R. Prinjha, A. Tarakhovsky, J. Ravetch, M. Nussenzweig (2014)
Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized MiceCell, 158
G. Alter, Maureen Martin, Nickolas Teigen, W. Carr, T. Suscovich, A. Schneidewind, H. Streeck, Michael Waring, A. Meier, C. Brander, J. Lifson, Todd Allen, M. Carrington, M. Altfeld (2007)
Differential natural killer cell–mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypesThe Journal of Experimental Medicine, 204
Y. Nishimura, R. Gautam, T. Chun, Reza Sadjadpour, K. Foulds, M. Shingai, F. Klein, A. Gazumyan, Jovana Golijanin, M. Donaldson, Olivia Donau, R. Plishka, A. Buckler-White, M. Seaman, J. Lifson, R. Koup, A. Fauci, M. Nussenzweig, Malcolma Martin (2017)
Early antibody therapy can induce long-lasting immunity to SHIVNature, 543
Ching-Lan Lu, Dariusz Murakowski, S. Bournazos, T. Schoofs, Debolina Sarkar, Ariel Halper-Stromberg, J. Horwitz, Lilian Nogueira, Jovana Golijanin, A. Gazumyan, J. Ravetch, M. Caskey, A. Chakraborty, M. Nussenzweig (2016)
Enhanced clearance of HIV-1–infected cells by broadly neutralizing antibodies against HIV-1 in vivoScience, 352
M. Abrahams, S. Joseph, N. Garrett, L. Tyers, M. Moeser, N. Archin, Olivia Council, David Matten, Shuntai Zhou, D. Doolabh, C. Anthony, N. Goonetilleke, S. Karim, D. Margolis, Sergei Pond, C. Williamson, R. Swanstrom (2019)
The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiationScience Translational Medicine, 11
T. Henrich, Zixin Hu, Jonathan Li, G. Sciaranghella, M. Busch, S. Keating, S. Gallien, N. Lin, Francoise Giguel, Laura Lavoie, V. Ho, P. Armand, R. Soiffer, M. Sagar, A. LaCasce, D. Kuritzkes (2013)
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation.The Journal of infectious diseases, 207 11
L. Shan, K. Deng, Neeta Shroff, C. Durand, S. Rabi, Hung‐Chih Yang, Hao Zhang, J. Margolick, J. Blankson, R. Siliciano, R. Siliciano (2012)
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.Immunity, 36 3
J. Reece, J. Petravic, M. Balamurali, L. Loh, S. Gooneratne, R. Rose, S. Kent, M. Davenport (2012)
An “Escape Clock” for Estimating the Turnover of SIV DNA in Resting CD4+ T CellsPLoS Pathogens, 8
S. Crowe (2018)
Faculty of 1000 evaluation for The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
G. Laird, C. Bullen, Daniel Rosenbloom, Alyssa Martin, A. Hill, C. Durand, J. Siliciano, R. Siliciano (2015)
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.The Journal of clinical investigation, 125 5
Sogaard (2015)
The depsipeptide romidepsin reverses HIV-1 latency in vivoPLoS Pathog, 11
Gonzalo Tapia, J. Højen, M. Ökvist, R. Olesen, S. Leth, S. Nissen, D. VanBelzen, Una O'Doherty, A. Mørk, Kim Krogsgaard, O. Søgaard, Lars Østergaard, M. Tolstrup, G. Pantaleo, M. Sommerfelt (2017)
Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs.The Journal of infection, 75 6
J. Petravic, Alexey Martyushev, J. Reece, S. Kent, M. Davenport (2014)
Modeling the Timing of Antilatency Drug Administration during HIV TreatmentJournal of Virology, 88
M. Caskey, F. Klein, J. Lorenzi, M. Seaman, A. West, Noreen Buckley, G. Kremer, Lilian Nogueira, Malte Braunschweig, J. Scheid, J. Horwitz, I. Shimeliovich, Sivan Ben-Avraham, M. Witmer-Pack, M. Platten, C. Lehmann, L. Burke, T. Hawthorne, R. Gorelick, B. Walker, T. Keler, R. Gulick, G. Fätkenheuer, S. Schlesinger, M. Nussenzweig (2015)
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117Nature, 522
C. Brinkmann, J. Højen, T. Rasmussen, A. Kjær, R. Olesen, P. Denton, L. Østergaard, Zhengyu Ouyang, M. Lichterfeld, Xu Yu, O. Søgaard, C. Dinarello, M. Tolstrup (2018)
Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory ResponsesmSphere, 3
N. Archin, A. Liberty, A. Kashuba, S. Choudhary, J. Kuruc, A. Crooks, D. Parker, E. Anderson, M. Kearney, M. Strain, D. Richman, M. Hudgens, R. Bosch, J. Coffin, J. Eron, D. Hazuda, D. Margolis (2012)
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapyNature, 487
C. Niu, Li Li, S. Daffis, J. Lucifora, M. Bonnin, S. Maadadi, E. Salas, Ruth Chu, Hilario Ramos, Christine Livingston, R. Beran, A. Garg, S. Balsitis, D. Durantel, F. Zoulim, W. Delaney, S. Fletcher (2017)
Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.Journal of hepatology, 68 5
Line Vibholm, M. Schleimann, J. Højen, T. Benfield, Rasmus Offersen, K. Rasmussen, R. Olesen, A. Dige, J∅rgen Agnholt, Judith Grau, M. Buzón, B. Wittig, M. Lichterfeld, A. Petersen, Xutao Deng, M. Abdel-Mohsen, S. Pillai, S. Rutsaert, Wim Trypsteen, W. Spiegelaere, Linos Vandekerchove, L. Østergaard, T. Rasmussen, P. Denton, M. Tolstrup, O. Søgaard (2017)
Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus InfectionClinical Infectious Diseases, 64
E. Borducchi, Jinyan Liu, Joseph Nkolola, Anthony Cadena, Wen-Han Yu, S. Fischinger, Thomas Broge, P. Abbink, N. Mercado, A. Chandrashekar, David Jetton, L. Peter, K. McMahan, Edward Moseley, Elena Bekerman, J. Hesselgesser, Wenjun Li, M. Lewis, G. Alter, R. Geleziunas, D. Barouch (2018)
Antibody and TLR7 Agonist Delay Viral Rebound in SHIV-Infected MonkeysNature, 563
(2020)
Safety and analytic treatment interruption outcomes of Vesatolimod in HIV controllers
(2020)
A randomized trial of the impact of 3BNC117 and romidepsin on the HIV-1 reservoir
J. Brodin, F. Zanini, L. Thebo, C. Lanz, G. Bratt, R. Neher, J. Albert (2016)
Establishment and stability of the latent HIV-1 DNA reservoireLife, 5
T. Rasmussen, M. Tolstrup, H. Møller, C. Brinkmann, R. Olesen, C. Erikstrup, A. Laursen, L. Østergaard, O. Søgaard (2015)
Activation of Latent Human Immunodeficiency Virus by the Histone Deacetylase Inhibitor Panobinostat: A Pilot Study to Assess Effects on the Central Nervous SystemOpen Forum Infectious Diseases, 2
S. Leth, M. Schleimann, S. Nissen, J. Højen, R. Olesen, Mette Graversen, S. Jørgensen, A. Kjær, P. Denton, A. Mørk, M. Sommerfelt, K. Krogsgaard, L. Østergaard, T. Rasmussen, M. Tolstrup, O. Søgaard (2016)
Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.The lancet. HIV, 3 10
D. Finzi, J. Blankson, J. Siliciano, J. Margolick, K. Chadwick, T. Pierson, Kendall Smith, J. Lisziewicz, F. Lori, C. Flexner, T. Quinn, R. Chaisson, E. Rosenberg, B. Walker, S. Gange, J. Gallant, R. Siliciano (1999)
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapyNature Medicine, 5
Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVJ2toCr/9wZZjwPUWvYES9l2nY+zyylnl33NGMK6MRsx on 10/02/2020 REVIEW URRENT Broadly neutralizing antibodies combined with PINION latency-reversing agents or immune modulators as strategy for HIV-1 remission a,b b Jesper Damsgaard Gunst , Jesper Falkesgaard Højen , a,b and Ole Schmeltz Søgaard Purpose of review Antiretroviral therapy (ART) is extremely effective in controlling HIV-1 infection; however, ART is not curative. Here, we review broadly neutralizing anti-HIV-1 antibodies (bNAbs) combined with latency- reversing agents (LRAs) or immune modulators as strategy for achieving long-term HIV-1 remission. Recent findings Clinical trials testing the effect of a single intervention such as a LRA ‘shock and kill’, immune modulator or bNAbs among HIV-1 infected individuals on long-term suppressive ART have not lead to long-term HIV-1 remission when ART is stopped. Novel combinations of interventions designed to eliminate infected cells and enhance immune-effector functions are being investigated. Findings in nonhuman primates (NHPs) of such combinations are very promising and clinical trials are now ongoing. These trials will provide the first indication of the efficacy of combinations of bNAbs and LRA or immune modulators for achieving durable HIV-1 remission. Summary bNAbs facilitate the elimination of HIV-1 infected cells and boost immune responses. Preclinical findings show that these effects
Current Opinion in HIV & AIDS – Wolters Kluwer Health
Published: Sep 1, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.